Company news

ENDRA Life Sciences Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ENDRA Life Sciences to Report First Quarter 2023 Financial Results on May 15, 2023

May 3, 2023

ENDRA Life Sciences Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Securities

May 1, 2023

ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering

April 27, 2023

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 13, 2023

ENDRA Life Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 14, 2023

March 6, 2023

ENDRA Life Sciences Announces 1-for-20 Reverse Stock Split

December 4, 2022

ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

ENDRA Life Sciences to Report Third Quarter 2022 Financial Results on November 14, 2022

November 8, 2022

ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of Two U.S. Patents

October 24, 2022

ENDRA Life Sciences Plans to Submit De Novo Request to U.S. FDA for its TAEUS® System in Coming Weeks

September 28, 2022

ENDRA Life Sciences Announces Issuance of 8th European Patent for its TAEUS® System

August 23, 2022

ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

August 14, 2022

ENDRA Life Sciences to Report Second Quarter 2022 Financial Results on August 15, 2022

August 3, 2022

ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices

August 1, 2022

ENDRA Life Sciences Awarded Two Additional Chinese Patents for its TAEUS® System

July 10, 2022

ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of 28th U.S. Patent

June 27, 2022

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with Issuance of 27th U.S. Patent

May 24, 2022

ENDRA Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022

ENDRA Life Sciences Issued Additional U.S. and Chinese Patents for its TAEUS® System

May 9, 2022

ENDRA Life Sciences to Report First Quarter 2022 Financial Results on May 12, 2022

May 1, 2022

ENDRA Life Sciences Raises $8.7 Million in Gross Proceeds Through its At-The-Market Facility

April 20, 2022

ENDRA Life Sciences Achieves Key Quality Management System Certification

March 30, 2022

ENDRA Life Sciences Strengthens TAEUS® System Global Intellectual Property Protection with Issuance of 10th and 11th Chinese Patents

March 29, 2022

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 29, 2022

ENDRA Life Sciences to Report Fourth Quarter 2021 Financial Results on March 30, 2022

March 21, 2022

ENDRA Life Sciences Strengthens TAEUS® System Intellectual Property with Issuance of 24th U.S. Patent

March 7, 2022

ENDRA Life Sciences Strengthens TAEUS® System Global Intellectual Property Portfolio with Issuance of 6th and 7th European Patents

February 10, 2022

ENDRA Life Sciences Provides Update on U.S. Regulatory Strategy for its TAEUS® System

February 8, 2022

ENDRA Life Sciences Expands into China with Shanghai General Hospital Partnership

January 23, 2022

ENDRA Life Sciences Announces New Clinical Study Partnership with King’s College Hospital, London

December 12, 2021

ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study

November 28, 2021

ENDRA Life Sciences Further Strengthens TAEUS® System Intellectual Property with Issuance of 22nd and 23rd U.S. Patents

November 15, 2021

ENDRA Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

November 14, 2021

ENDRA Life Sciences to Report Third Quarter 2021 Financial Results on November 15, 2021

November 7, 2021

ENDRA Life Sciences Further Strengthens TAEUS® System Intellectual Property Protection with Issuance of 21st U.S. Patent

October 12, 2021

ENDRA Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

August 11, 2021

ENDRA Life Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

August 1, 2021

ENDRA Life Sciences Announces Participation in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021

July 19, 2021

ENDRA Life Sciences Strengthens TAEUS(R) System Intellectual Property Protection with the Issuance of Three U.S. Patents

July 6, 2021

ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

June 14, 2021

ENDRA Life Sciences Set to Join the Russell Microcap(R) Index

June 8, 2021

ENDRA Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update

May 16, 2021

ENDRA Life Sciences to Report First Quarter 2021 Financial Results on May 17, 2021

May 5, 2021

ENDRA Life Sciences Further Strengthens TAEUS(R) System's Intellectual Property Protection with Issuance of Two U.S. Patents

May 3, 2021

ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update

March 24, 2021

ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials

March 17, 2021

ENDRA Life Sciences to Report Fourth Quarter 2020 Financial Results on March 25, 2021

March 16, 2021

ENDRA Life Sciences Announces New Clinical Study Partnership with Inselspital University Hospital in Bern, Switzerland

February 16, 2021

ENDRA Life Sciences Further Strengthens TAEUS(R) System Intellectual Property Protection with Issuance of 14th U.S. Patent

January 25, 2021

ENDRA Life Sciences Granted 13th U.S. Patent for its TAEUS(R) Platform Technology

January 12, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.